Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Patidegib

Small molecule · Inhibitor of Smoothened receptor (SMO) · developed by Sol-Gel Technologies

Phase 3 Most advanced trial (none active)
SLGL Developer
2 Registered trials

What is Patidegib?

Patidegib is a topical gel containing a cyclopamine-derived inhibitor that binds the G-protein coupled receptor smoothened (SMO) and blocks Hedgehog pathway signaling, reducing proliferation and survival of tumor cells with overactive Hedgehog signaling. It is applied locally to limit systemic exposure and is studied in basal cell nevus syndrome (Gorlin syndrome).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Smoothened receptor (SMO)
Mechanism
Inhibitor of Smoothened receptor (SMO)
Pathways
Hedgehog signaling pathway
Therapy area
Oncology
Developer
Sol-Gel Technologies, Ltd. (SLGL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06050122 Phase 3 Gorlin Syndrome Completed SLGL
NCT04308395 Phase 3 Basal Cell Nevus Syndrome Terminated SLGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Basal Cell Nevus SyndromeGorlin Syndrome

More from Sol-Gel Technologies

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SLGL page.

Follow SLGL, the company behind Patidegib

See SLGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SLGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.